Evidence map›Paper›PMID 41482115›Full record

ArticleChest2026

High-Throughput Proteomics in Lymphangioleiomyomatosis: Premelanosome Protein as a Diagnostic Biomarker, Construction of a Diagnosis Score, and Evidence of Neutrophil Involvement.

Rémi Diesler, Tiegang Han, Wendy K Steagall, Samer Salem, Damir Khabibullin, Joelle Chami, Brooke Squitieri, Amanda M Jones, Patricia Julien-Williams, Tania Machado and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rémi DieslerNational Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, UMR 754, INRAE, Claude Bernard University Lyon 1, Lyon, France; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Electronic address: remi.diesler01@chu-lyon.fr.
Tiegang HanDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Wendy K SteagallCritical Care Medicine and Pulmonary Branch, Bethesda, MD.
Samer SalemDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Damir KhabibullinDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Joelle ChamiDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Brooke SquitieriDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Amanda M JonesCritical Care Medicine and Pulmonary Branch, Bethesda, MD.
Patricia Julien-WilliamsCritical Care Medicine and Pulmonary Branch, Bethesda, MD.
Tania MachadoOffice of the Clinical Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Tat'Yana WorthyOffice of the Clinical Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Gustavo Pacheco-RodriguezCritical Care Medicine and Pulmonary Branch, Bethesda, MD.
Yan TangDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Caroline LerouxIVPC UMR754, INRAE, Université Claude Bernard Lyon 1, EPHE, Université PSL, Lyon, France.
Vincent CottinNational Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, UMR 754, INRAE, Claude Bernard University Lyon 1, Lyon, France.
Heng-Jia LiuCenter for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China; Department of Biomedical Sciences, College of Medicine and Veterinary Medicine, Edinburgh Medical School, University of Edinburgh, Edinburgh, Scotland.
Souheil El-ChemalyDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Francis X McCormackDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
Joel MossDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Elizabeth P HenskeDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Funding

The Molecular and Genetic Pathogensis of LAMU01HL131022 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HENSKE, ELIZABETH P · 2016 to 2024
$5.7M
NHLBI NIH HHS U01 HL131022
6 · The paper itself

Abstract

backgroundLymphangioleiomyomatosis is an incurable cystic lung disease primarily affecting female individuals whose pathophysiologic features are only partially elucidated. Vascular endothelial growth factor D (VEGF-D) is a diagnostic biomarker for lymphangioleiomyomatosis, but about one-third of patients have low levels, necessitating invasive lung biopsy. RESEARCH QUESTION: Does high-throughput proteomics reveal new diagnostic biomarkers and disease mechanisms in lymphangioleiomyomatosis? STUDY DESIGN AND

methodsWe used the high-throughput proteomic Somascan assay (Somalogic) to measure approximately 10,000 plasma proteins in 20 patients with lymphangioleiomyomatosis and 10 healthy control participants. Enzyme-linked immunosorbent assay (ELISA) confirmed key protein levels in a validation cohort for a total of 53 patients with lymphangioleiomyomatosis and 64 control participants. A least absolute shrinkage and selection operator logistic regression model was used to develop a multiprotein diagnostic score.

resultsWe identified 662 differentially expressed proteins. Matrix metalloproteinase 8 (MMP8) was the top upregulated protein in the plasma of patients with lymphangioleiomyomatosis, and neutrophil degranulation was the most enriched pathway. Fifty-eight neutrophil proteins were enriched in lymphangioleiomyomatosis plasma. Premelanosome protein (PMEL) was 2-fold higher in the plasma of patients with lymphangioleiomyomatosis (log

interpretationOur comprehensive proteomic analysis highlights the potential role of neutrophils in lymphangioleiomyomatosis pathogenesis, with MMP8 and other proteases as potential drivers of lung destruction. PMEL and the 6-protein LAMScore are promising biomarkers for lymphangioleiomyomatosis, especially in patients with low VEGF-D levels. The high precision and reproducibility, the wide array of analytes measured, and the lowering costs of proteomics platforms indicate that in the future, lymphangioleiomyomatosis diagnosis could rely on clinically approved custom analyte panels without lung biopsy.

Indexed as

Lung NeoplasmsLymphangioleiomyomatosisMatrix Metalloproteinase 8NeutrophilsProteomicsAdultBiomarkersBiomarkers, TumorCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansMiddle AgedVascular Endothelial Growth Factor DBiomarkersBiomarkers, TumorMatrix Metalloproteinase 8MMP8 protein, humanVascular Endothelial Growth Factor Ddiagnosis scoreLASSOlymphangioleiomyomatosisMMP8neutrophilsPMELpremelanosome protein

Identifiers

PMID41482115
PMCPMC13181220

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.